AGILE trial reports on antiviral activity of molnupiravir in vaccinated and unvaccinated individuals infected with contemporaneous variants of SARS-CoV-2
The antiviral drug molnupiravir received regulatory approval for treating people … Continued
Learning and confirming in publicly funded antiviral trials
Reporting the phase 2 results from the UK AGILE CST-2 … Continued
Groundbreaking COVID-19 treatments to be fast-tracked through clinical trials
The world’s most innovative treatments for COVID-19 will soon be … Continued
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) … Continued
AGILE Press release: Search for effective COVID-19 treatments
The University of Liverpool, Liverpool School of Tropical Medicine and Southampton Clinical Trials Unit announced this week that they have launched their innovative COVID-19 drug testing platform, AGILE. The AGILE initiative is a collaboration between the University of Liverpool, Liverpool School of Tropical Medicine, Southampton Clinical Trials Unit, University of Southampton and Lancaster University, as well as other partners. AGILE has been developed by Infectious Diseases clinicians, clinical and pre-clinical pharmacologists, clinical trials specialists and statisticians. The result is a clinical trials platform that can test new drugs for COVID-19 and identify faster than ever before those compounds which could be game changers in the battle against COVID-19………